In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Marconi Corp. PLC

www.marconi.com

Latest From Marconi Corp. PLC

European Biotechs Resort to Layoffs

Since redundancies in Europe are expensive and politically sensitive, companies have tended, where possible, to find other ways of cutting costs. The prolonged biotech winter is leaving many European biotechs with few options besides layoffs, however.
BioPharmaceutical Europe

Proteomics Firms Turn to IT for Database Upgrade

Proteomics companies don't want to be seen as database providers, a low-valuation model once pursued by Celera and Incyte. So companies like Myriad Genetics and Oxford GlycoSciences have spun out their database businesses into JVs with IT partners, which provide cash and technology. Both partners benefit: biotechs get valued as budding drug developers and retain access to these tools, while IT companies get a foot in the door of the life sciences markets into which they wish to expand their products and services.
BioPharmaceutical Strategy

UCL Ventures (University College London)

Spin-out activity at UCL Ventures was jump-started by the success of one company, SR Pharma, during the late nineties. The tech transfer office now takes advantage of London's status as a business and financial center to find and develop new entrepreneurs, and continues to benefit from UK government seed funds.
BioPharmaceutical Strategy

Accuray: Tightly Targeting Tumors

While open surgery remains the traditional primary treatment option for solid tumors, ten years ago a procedure called frame-based radiosurgery was commercially introduced in the US to treat brain tumors. Radiosurgery uses an intense dose of high energy radiation to destroy a tumor with precise targeting in order to avoid damaging healthy tissue. This requires patients to have a stereotactic metal frame screwed into their skulls to accurately target the tumor. The frame also limits radiosurgery's applicability largely to intracranial tumors, which constitute only 10% of all solid tumors. Accuray has developed a frameless radiosurgery system, the CyberKnife, which has proven effective in treating head and neck tumors without the frame's discomfort, and is looking to expand its application to other body tumors. Having survived several rocky periods since its 1990 launch, Accuray must now show it can survive selling capital equipment, an area historically harsh on start-up companies, both in terms of competing against larger entrenched competitors and in convincing customers to acquire new costly systems.
Medical Device Middle East and Africa
See All

Company Information

  • Industry
  • Medical Devices
  • Therapeutic Areas
  • Alias(es)
  • General Electric Co. PLC
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • UK
  • Parent & Subsidiaries
  • Marconi Corp. PLC
  • Senior Management
  • MWJ Parton, CEO
    D. Newlands, Fin.
    R. Williams, Bus. Dev.
    Mark E Furth, SVP, Research
  • Contact Info
  • Marconi Corp. PLC
    Phone: (44) 71 493 8484
    1 Stanhope Gate
    London, W1A 1EH
    UK
Advertisement
Advertisement
UsernamePublicRestriction

Register